PF 06463922 - Lorlatinib

Based on 20 reference(s) in Google Scholar 80 100 20

Axon 2600

CAS [1454846-35-5]

MF C21H19FN6O2
MW 406.41

  • Purity: 99%
  • Optical purity: Optically pure
  • Soluble in DMSO

PF 06463922


Potent, orally available and brain-penetrant ALK/ROS1 selective inhibitor (mean Ki value of <0.07 nM for inhibition of recombinant human wild-type ALK) displaying superior potency against all known clinically acquired ALK mutations (all displaying sub-nanomolar Ki values), including the highly resistant G1202R mutant. PF 06463922 (Lorlatinib) is capable of blocking Crizotinib-resistant ROS1 mutations and treatment with PF 06463922 led to superior regression of EML4-ALK-driven brain metastases compared with other clinically available ALK inhibitors.

KEYWORDS: PF 06463922 | supplier | ALK/ROS1 inhibitor | Lorlatinib | PF06463922 | CAS [1454846-35-5] | ALK | ROS | Inhibitor | RTK | receptor tyrosine kinase | c-ROS | G1202R | mutant | Crizotinib | EML4-ALK | oncogene | fusion protein | Anaplastic Lymphoma Kinase | insulin receptor

Size Unit Price Stock
5 mg €105.00 In Stock
25 mg €385.00 In Stock
Need more? Bulk Inquiry

The purity of Axon Ligands™ is confirmed by HPLC-MS, 1H-NMR and/or microanalysis. Analytical data are available upon request.

Caution: Axon Ligands™ are not fully tested. They are for research purposes only! Not for human consumption!

Please wait...